Letermovir

Chemical formula: C₂₉H₂₈F₄N₄O₄  Molecular mass: 572.561 g/mol 

Therapeutic indications

Letermovir is indicated for:

Prophylaxis of cytomegalovirus (CMV) after allogeneic haematopoietic stem cell transplantation

Population group: only adults (18 years old or older)

Letermovir is indicated for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Letermovir is contraindicated in the following cases:

Pimozide

Pimozide

Ergot alkaloids

Ergot alkaloids

St. John's wort (Hypericum perforatum)

Hypericum perforatum (St John's Wort)

Atorvastatin, ciclosporin

Atorvastatin and additionally Ciclosporin

Simvastatin, pitavastatin, rosuvastatin, ciclosporin

at least one of
Simvastatin
Pitavastatin
Rosuvastatin
and additionally Ciclosporin

Dabigatran, ciclosporin

Dabigatran and additionally Ciclosporin

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2020: PREVYMIS Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈